- Home
- MREO vs JRI Comparison
MREO vs JRI Comparison
Compare MREO & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- JRI
- Stock Information
- Founded
- MREO 2015
- JRI 2012
- Country
- MREO United Kingdom
- JRI United States
- Employees
- MREO N/A
- JRI N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- JRI Finance Companies
- Sector
- MREO Health Care
- JRI Finance
- Exchange
- MREO Nasdaq
- JRI Nasdaq
- Market Cap
- MREO 424.5M
- JRI 349.3M
- IPO Year
- MREO N/A
- JRI N/A
- Fundamental
- Price
- MREO $2.41
- JRI $12.99
- Analyst Decision
- MREO Strong Buy
- JRI
- Analyst Count
- MREO 7
- JRI 0
- Target Price
- MREO $7.71
- JRI N/A
- AVG Volume (30 Days)
- MREO 1.5M
- JRI 68.0K
- Earning Date
- MREO 05-19-2025
- JRI 01-01-0001
- Dividend Yield
- MREO N/A
- JRI 9.38%
- EPS Growth
- MREO N/A
- JRI N/A
- EPS
- MREO N/A
- JRI N/A
- Revenue
- MREO N/A
- JRI N/A
- Revenue This Year
- MREO N/A
- JRI N/A
- Revenue Next Year
- MREO $56.11
- JRI N/A
- P/E Ratio
- MREO N/A
- JRI N/A
- Revenue Growth
- MREO N/A
- JRI N/A
- 52 Week Low
- MREO $1.58
- JRI $9.70
- 52 Week High
- MREO $5.02
- JRI $12.12
- Technical
- Relative Strength Index (RSI)
- MREO 50.36
- JRI 58.97
- Support Level
- MREO $2.28
- JRI $12.68
- Resistance Level
- MREO $2.75
- JRI $13.13
- Average True Range (ATR)
- MREO 0.16
- JRI 0.20
- MACD
- MREO -0.00
- JRI 0.05
- Stochastic Oscillator
- MREO 27.66
- JRI 83.91
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its strategy involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.